Overexpression of MDM2 by gene amplification or single nucleotide polymorphism is documented in many cancer types, and the occurrence of p53 mutations and overexpression of MDM2 are usually mutually exclusive, supporting the notion that MDM2 overexpression is responsible for driving the cancer phenotype by abolishing p53 activity [13–15]. The gene discussed is TP53; the disease is cancer.